William R. Schelman

1 month ago | accp1.onlinelibrary.wiley.com | Martha Gonzalez |Martha González |Zhao Yang |William R. Schelman |Thomas C. Marbury

Introduction Fruquintinib (FRUZAQLATM) is a highly selective, oral, small-molecule tyrosine kinase inhibitor of all three vascular endothelial growth factor receptors (VEGFRs), -1, -2, and -3.1, 2 Fruquintinib was initially approved in China for the treatment of metastatic colorectal cancer (mCRC) in patients who had failed two prior lines of systemic therapy.3, 4 It was then approved in the United States in November 2023 for the treatment of adult patients with mCRC who have been previously...